New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
06:09 EDTAZN, GE, AAPL, GSK, BEN, DELLOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: GE (GE) is the world's top producer of aircraft engines and medical imaging equipment, but as far as its profits are concerned, itís very much a bank. GE Capital is expected to account for nearly half the company's 2012 profit, the Wall Street Journal reports...Dellís (DELL) potential $23B leveraged buyout could also be the deal that finally gets the leveraged-buyout machine going again, showering financiers in fees and potentially yielding big returns for investors, the Wall Street Journal reports...REUTERS: Americans are more confident in the future and are increasingly striking out to set up their own homes, a move that is helping propel the housing recovery, Reuters reports...When U.S. natural gas producers release their 2012 annual reports, many companies may have to significantly reduce a key indicator of their financial health: reserves. The SEC requires companies to calculate and report year-end oil and gas reserves using 12-month average prices, Reuters reports...BLOOMBERG: With the worst flu outbreak since 2009 gripping the U.S., vaccine makers (GSK, AZN) are determined to do better next season. Theyíre developing powerful vaccines that hold the promise of cutting incidences of flu by the thousands, Bloomberg reports...Franklin Templeton Investments (BEN) reduced its holdings of Apple (AAPL) last year to 4.2% from 7% in 2011 on concern the maker of the iPhone lacks a strategy to sell cheaper smartphones in emerging markets such as China and India, Bloomberg reports.
News For GE;DELL;GSK;AZN;BEN;AAPL From The Last 14 Days
Check below for free stories on GE;DELL;GSK;AZN;BEN;AAPL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 3, 2014
09:37 EDTGSKAmgen to pay GlaxoSmithKline $275M to terminate denosumab collaboration pact
Subscribe for More Information
09:37 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:30 EDTGE, AAPLApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
07:40 EDTAAPLApple bulls bet new products to prompt stock revival, Bloomberg says
Subscribe for More Information
April 2, 2014
16:58 EDTAAPLPiper Jaffray still expects 'full TV' offering from Apple this year
Subscribe for More Information
16:21 EDTAAPLOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTAAPLOptions Update; April 2, 2014
Subscribe for More Information
12:48 EDTAAPLGT Advanced rallies after Goldman raises price target
Shares of GT Advanced Technologies (GTAT) - which makes sapphire products and solar energy equipment - are climbing after Goldman Sachs raised its price target on the stock in a note to investors earlier today. WHAT'S NEW: Goldman Sachs analyst Brian Lee raised his 2015 and 2016 earnings per share estimates for GT Advanced, as he is more upbeat about the outlook for the company's equipment business. GT Advanced's deal to supply sapphire for upcoming Apple (AAPL) devices is worth $15 per share for GT if the deal goes as expected, and up to $25 if the deal exceeds expectations, contended Lee. The analyst raised his price target on the stock to $24 from $20 and kept a Buy rating on the shares. OTHERS TO WATCH: Rubicon Technology (RBCN) also makes sapphire. That stock was upgraded to Overweight from Neutral in a note to investors from JPMorgan yesterday. JPMorgan expected Rubicon to benefit from a pick-up in demand for LEDs and sapphire covers. The stock surged yesterday in the wake of the upgrade. PRICE ACTION: In early afternoon trading, GT Advanced climbed $1.13, or 6.5%, to $18.51, while Rubicon fell 2.8% to $12.62.
11:15 EDTAAPLAmazon says Fire TV 'three times as powerful' as Apple TV, Roku, Chromecast
09:35 EDTAAPLActive equity options trading on open
Subscribe for More Information
09:18 EDTAAPL, GSKOn The Fly: Pre-market Movers
Subscribe for More Information
08:32 EDTGEGE gas engine technology to be used by integrated gasified biomass power plant
Subscribe for More Information
07:45 EDTGEGE Healthcare to acquire CHCA Computer Systems, terms not disclosed
Subscribe for More Information
07:44 EDTGSKAgenus down 9.4% after GlaxoSmithKline stops MAGRITi Phase 3 trial
Subscribe for More Information
07:23 EDTAAPLApple (AAPL) to act like Google (GOOG) in ad push, Business Insider says
Subscribe for More Information
06:45 EDTAAPLAmazon expected to announce media streaming device today, Business Insider says
Subscribe for More Information
06:11 EDTGSKGlaxoSmithKline confirms plans to stop MAGRIT Phase III trial
GlaxoSmithKline announced its decision to stop the MAGRITi trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer patients, after establishing that it will not be possible to identify a sub-population of gene-signature positive NSCLC patients that may benefit from the treatment. Data from the trial announced on 20 March 2014 showed that it did not meet its first or second co-primary endpoints as it did not significantly extend disease-free survival when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy. The trial will be stopped and GSK will now gain access to the un-blinded data, in order to conduct a full assessment of the findings and understand learnings for other aspects of immunotherapy development within GSK. The Independent Data Monitoring Committee indicated that its review of the current safety information revealed no specific safety concern and the data is in line with the known safety information for the MAGE-A3 cancer immunotherapeutic.
05:58 EDTAAPLSamsung lawyer calls Apple claims 'gross exaggeration,' Re/code reports
Subscribe for More Information
05:57 EDTAAPLPiper positive on Apple shares ahead of product cycle
Subscribe for More Information
05:45 EDTGSKAgenus announces GSK's MAGE-A3 Phase 3 study will be stopped
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use